Source à consulter
OpenAI announced today that it has acquired Orchestra Bio Inc., a startup specializing in drug development software. Orchestra builds AI agents that help pharmaceutical teams keep development programs on track.
Orchestra's technology will be integrated into OpenAI's Rosalind life sciences unit, which focuses on applying AI in the fields of health and biology.
This acquisition is expected to enable OpenAI to develop more effective tools for pharmaceutical teams, helping to accelerate the drug development process.
Consulter la source ↗SiliconANGLE AI
Titre et date issus du flux; image déclarée par la page source, réponse image vérifiée. Synthèse à relire.
← Continuer à explorer